Locally, we have observed that adherence to breast cancer risk management of BRCA1/2 PV/LPV carriers is much higher than ovarian cancer risk management [26] – warranting further investigation into the support and informational needs of carriers to make risk management decisions. This evidence concerns the gene BRCA1 and ovarian cancer.